Additional resources for you and your patient

Professional organizations and resources


 



 

American Society of Hematology

American Society of Hematology (ASH): The premiere professional organization in hematology, ASH provides the latest hematology research, treatment guidelines, and educational programs


 



 

American Society of Pediatric Hematology and Oncology (ASPHO)

American Society of Pediatric Hematology and Oncology (ASPHO): ASPHO is dedicated to researching, treating, and educating about bleeding disorders in the pediatric community


 



 

American Thrombosis and Hemostasis Network

American Thrombosis and Hemostasis Network (ATHN): ATHN partners with treatment centers to form a national database of patient health information, which enables clinicians to gain more information about bleeding and blood disorders


 



 

International Society on Thrombosis and Haemostasis

International Society of Thrombosis and Haemostasis (ISTH): A global not-for-profit organization, ISTH is a global network of healthcare providers treating, researching, and educating on bleeding disorders


 



 

PubMed

PubMed: PubMed is a searchable database of indexed publications, including science journals and online books


 



 

Patient advocacy groups


 



 

Hemophilia Federation of America

Hemophilia Federation of America (HFA): The HFA strives to form connections between patients and caregivers within the bleeding disorders community, and advocates for the development and use of safe, affordable treatments


 



 

National Hemophilia Foundation

National Hemophilia Foundation (NHF): The NHF is the largest national non-profit organization dedicated to education, advocacy, and research of inheritable bleeding disorders


 



 

World Federation of Hemophilia

World Federation of Hemophilia (WFH): The WFH is committed to improving and sustaining excellent care for people with bleeding disorders across the world


 



 

Novo Nordisk initiatives


 



 

Novo Nordisk Youtube channel

Novo Nordisk YouTube® channel: This video series highlights the work being done to increase the knowledge and understanding of hemophilia within society and provides patients and caregivers with the resources and support they need to live well with hemophilia


 



 

Novo Nordisk Facebook Page

Novo Nordisk Facebook® page: Join the Novo Nordisk community via their Facebook page


 



 

Hemophilia Experiences, Results and Opportunities (HERO) program

Hemophilia Experiences, Results, and Opportunities (HERO): HERO is an international, multidisciplinary initiative guided by the HERO International Advisory Board and supported by Novo Nordisk


 



 

Contact with a Novoeight Hemophilia Therapy Sales Manager

Talk with us

Connect with a local Novo Nordisk Representative to learn more about Novoeight®. He or she is an excellent source for information, and can direct you to many helpful tools and resources.

Click here for a list of vendors

How to Order Novoeight®

Click here for a list of vendors who distribute Novoeight®.


 



 

Selected Important Safety Information

Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight® or its components, including hamster proteins.

Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight® and administer appropriate treatment.

Indications and Usage

Novoeight® (Antihemophilic Factor [Recombinant]) is indicated for use in adults and children with hemophilia A for control and prevention of bleeding, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes.

Novoeight® is not indicated for the treatment of von Willebrand disease.
 

Important Safety Information

Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight® or its components, including hamster proteins.

Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight® and administer appropriate treatment.

Development of activity-neutralizing antibodies (inhibitors) may occur.  If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an appropriate dose, perform an assay that measures factor VIII inhibitor concentration.

The most frequently reported adverse reactions (≥0.5%) were injection site reactions, increased hepatic enzymes, and pyrexia.


Please click here for Novoeight® Prescribing Information.